Based on the Beta Drugs Ltd. stock forecast from 1 analysts, the average analyst target price for Beta Drugs Ltd. is INR 1,600.00 over the next 12 months. Beta Drugs Ltd.’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Beta Drugs Ltd. is Neutral, which is based on 0 positive signals and 0 negative signals. At the last closing, Beta Drugs Ltd.’s stock price was INR 1,682.35. Beta Drugs Ltd.’s stock price has changed by -11.09% over the past week, -0.11% over the past month and 0% over the last year.
No recent analyst target price found for Beta Drugs Ltd.
No recent average analyst rating found for Beta Drugs Ltd.
Frequently Asked Questions About Beta Drugs Ltd. (BETA:NSE) Stock
Based on ratings from 1 analysts Beta Drugs Ltd.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on BETA:NSE's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for BETA:NSE is INR 1,600.00 over the next 12 months. The maximum analyst target price is INR 1600 while the minimum anlayst target price is INR 1600.
Unfortunately we do not have enough data on BETA:NSE's stock to indicate if its overvalued.
The last closing price of BETA:NSE's stock was INR 1,682.35.
Unfortunately we do not currently have any market capitalization data for BETA:NSE's stock.
Based on targets from 1 analysts, the average taret price for BETA:NSE is projected at INR 1,600.00 over the next 12 months.
This means that BETA:NSE's stock price may go down by -4.89% over the next 12 months.
We can't find any ETFs which contains Beta Drugs Ltd.'s stock.
Sorry, we do not have any data on the number of employees for Beta Drugs Ltd..
Sorry we do not have any infomation available on Beta Drugs Ltd.'s address.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
There is nothing we particularly dislike
Frequently Asked Questions About Beta Drugs Ltd. (BETA:NSE) Stock
Based on ratings from 1 analysts Beta Drugs Ltd.'s stock is Strong Buy. Stock Target Advisor's fundamental analysis is Neutral. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on BETA:NSE's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for BETA:NSE is INR 1,600.00 over the next 12 months. The maximum analyst target price is INR 1600 while the minimum anlayst target price is INR 1600.
Unfortunately we do not have enough data on BETA:NSE's stock to indicate if its overvalued.
The last closing price of BETA:NSE's stock was INR 1,682.35.
Unfortunately we do not currently have any market capitalization data for BETA:NSE's stock.
Based on targets from 1 analysts, the average taret price for BETA:NSE is projected at INR 1,600.00 over the next 12 months.
This means that BETA:NSE's stock price may go down by -4.89% over the next 12 months.
We can't find any ETFs which contains Beta Drugs Ltd.'s stock.
Sorry, we do not have any data on the number of employees for Beta Drugs Ltd..
Sorry we do not have any infomation available on Beta Drugs Ltd.'s address.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BETA:NSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
